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Abstract  Epidemic meningococcal 
meningitis is a major public health 
problem still affecting tropical 
countries, particularly in  
Sub-Saharan Africa, which lies 
within African meningitis belt.  
Repeated large scale epidemics of 
CSM have been reported in north-
ern Nigeria for the past four  
decades. It is one of the important 
causes of morbidity and mortality in 
these regions. Mortality from the 
CSM remains high despite  
advances in treatment  
modalities. Neisseria meningitidis 
serogroup A have been the major 
cause of large scale epidemics in 
tropical countries, while serogroups 
B, C, Y and W-135 are responsible 
for most of invasive disease in 
America and other developed coun-
tries. 
Objective: To determine the pattern 
of epidemic CSM in children at 
Federal Medical Centre, Gusau. 
Method: The study was a retrospec-
tive one carried out in children aged 
six months to 12 years admitted 
into Emergency Paediatrics Unit 
(EPU) with a diagnosis of CSM 
within the period January to May, 
2009. 
Results: Seventy- seven children 
with epidemic CSM were admitted 
and managed in EPU from January- 
May 2009. 
Conclusion: Neisseria meningitidis 
serogroup A CSM is becoming the 
disease of young infants, and 
stresses the need for inclusion of 
CSM vaccine in early infancy in 
routine immunization policy, in 




Epidemic meningococcal meningitis is a major public 
health problem still affecting tropical countries, particu-
larly in sub-Saharan Africa, which lies in the African 
meningitis belt.1Repeated large scale epidemics have 
been reported in the 21st Century, about 200 years after 
the disease was first reported in Geneva, Switzerland. It 
is one of the important causes of morbidity and mortal-
ity in these regions. Mortality from the disease remains 
high, despite  major achievement in the treatment mo-
dalities. It was reported that about 10% of patients who 
had the disease will not survive despite effective reat-
ment.2Neisseria meningitidis have been separated by 
sero-agglutination into nine serogroups A, B, C, D, X, 
Y, Z, W-135, and 29 E. Groups B, C, Y, and W-135 are 
responsible for most of invasive disease in America and 
other developed countries, whereas, group A and occa-
sionally group C account for large scale epidemics in 
many other countries particularly in sub-Saharan Af-
rica.3At Federal Medical CentreGusau, Zamfara State, in 
the north-western Nigeria, an epidemic Cerebrospinal 
meningitis (CSM) was observed in the year 2009. 
 
 
Subjects and Methods 
 
The study was a retrospective one carried out in children 
aged six months to 12 years admitted into EPU with a 
diagnosis of CSM within the study period January to 
May 2009. The folders of all the children with the diag-
nosis of CSM were retrieved. The approval of Federal 
Medical Centre Gusau Ethical Committee was sought 
for and obtained before the commencement of the study. 
Criteria for the diagnosis of CSM was adapted from the 
WHO practical guidelines for the control of epidemic 
meningococcal diseases.4Lumbar puncture was done on 
all patients after obtaining verbal consent from the par-
ents. Cerebrospinal fluid (CSF) was sent for micros-
copy, culture, sensitivity, and LPA. The bio-data, clini-
cal features, results of investigations, and outcome were 
extracted and analyzed. Simple statistical tables wre 






Seventy-seven children with epidemic CSM were admit-
ted from January 1st, to May 31st 2009. Over this period, 
564 children were admitted in to EPU giving overall 
prevalence rate of 13.7% (77 of 564). Fifty (64.9%) 
were males and 27 (35.1%) were females with a M:F 
ratio of 1.9:1. The ages ranged from six months to 12 
years with a mean age (±1 SD) 67.4± 38.8 months. 
 
Infections and age distribution:   
 
Thirty-seven (48.1%) and 32 (41.6%) were within the
ages of 6-10 and 1-5 years respectively, while 5 (6. %) 
patients were aged less than one year. Three (3.8%) of 




The major clinical presentations are those of fever, n ck 
stiffness, vomiting, convulsions, coma, and skin rash. 
Fever was present in all the patients (100%), while neck 
stiffness was seen in 74 (96.1%) cases. Vomiting and 
convulsions were seen in 38 (49.4%) and 35 (45.5%) 
patients respectively. Altered sensorium was present in 
26 (33.8%), while 12 (15.6%) had skin rash. 
 
Duration of illness prior to presentation to hospital: 
 
Forty- eight (62.3%) patients presented to hospital 
within 72 hours of onset of illness while 29 (37.7%) 
presented more than 72 hours after the onset of illness. 
Among the 29 patients who presented at more than 72 
hours after the onset of symptoms, 11 (14.3%) of them 




The monthly prevalence of epidemic CSM is shown in 
fig 1. The   highest prevalence was seen in April 
(23.6%), which was closely followed by that in March 
(21.6%). The prevalence in January was 3.3% while in 
February was 3.9%. The prevalence of cases dropped to 
10.5% in the month of May. 
 
Fig 1: Monthly prevalence of CSM in children. 
Laboratory results: 
 
The Latex Particle Agglutination was positive forNeis-
seria meningitidis serogroup A in all of the 77 CSF sam-
ples. Also five more patients had non-meningococcal 
meningitis during the epidemics ( 3 pneumococcus and 
2 Haemophilus influenzae). CSF culture was positive in 
only 5 (6.5%) patients with meningococcal meningitis. 
The five isolates were sensitive to ceftriaxone, chloram-
phenicol, and ciprofloxacin while resistant to penicillin. 
 
Duration of illness prior to presentation and outcomes: 
 
Fifty-seven (74.0%) patients recovered fully, 8 (10.4%) 
died, 6 (7.8%) had neurologic sequelae (visual 2, deaf-
ness 4) and 6 (7.8%) absconded.The age ranges for the 
fatal cases (7 months – 10 years)and those with neu-
rologic sequelae (6 months - 10 years) did not differ. 
Only two of the eight fatal cases presented to hospital 
within 72 hours of onset of illness while six are among 
those presenting later. Also, four of the six patients with 
neurologic sequelae presented beyond 72 hours after the 
onset of illness.  The risk of death is higher when the 
duration of illness prior to presentation was more than 
72 hours (2/48 versus 6/29; Fisher exact p = 0.03). There 
is no statistically significant relationship between neu-
rologic sequelae and duration of illness prior to presen-







Meningococcal meningitis is primarily the disease of 
young children, but in epidemic, even young infants 
may be affected. In this study, 40 (51.9%) of patients 
were aged six years and above while 32 (41.6%) were 
between one and five years age; out of which 11 
(34.4%) are young infants.  Five (6.5%) are below the
age of 1 year. The same pattern of age distribution have 
earlier been reported in Sokoto,5 in  contrast to what 
have been reported by Bwala et al6 in Maiduguri, north-
east, Nigeria. In Maiduguri, children less than 3 years of 
age, some of whom were infants constitute the major 
group affected. Also Idris Mohammed and co-workers7 
in Nigeria reported significant numbers of infants af-
fected during the large-scale epidemics of 1996.The 
reason for relative involvement of young infants as 
against previously observed pattern is not known, but 
virulence of clonal sub-groups might be contributory as 
suggested by Idris Mohammed and co-workers. Consid-
ering the relative involvement of young infants during 
epidemics, the immunization policy may need to be  
reviewed in order to incorporate CSM vaccine during 
early infancy into the routine National Immunization 
Programme of different countries within meningitis belt. 
One major set back for the polyvalent vaccines that have 
been in use for the past 30 years was poor immunogenic 
response in infants and young children, especially in 
those below the age of four years.  
 
Recently, a new meningococcal A conjugate vaccine 
which induces higher and more sustainable immune 
response even in young infants was introduced(WHO 
facts sheets/No 141) and may soon become widely used 
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across African meningitis belt.The seasonal pattern of 
the disease is similar to what was described by early 
workers.8,9The prevalence of the disease rises and 
reached its peak in the month of April. The average tem-
perature in Gusau and environs around the middle of 
April was 41Oc in association with low humidity. Late 
presentation to the hospital is a common problem in 
developing countries and this may favour poor outcome 
with resultant high morbidity and mortality. In this 
study, the mortality is higher in those patients presenting 
to the facility lately at more than 72 hours from the on-
set of the illness.  Also, neurologic sequelae was more in 
those patients  whose delay in presentation is more than 
72 hours. This stresses the need for public education on 
early recognition and prompt treatment. Owing to the
unfavourable outcome and documented evidence of effi-
cacy of intramuscular oily chloramphenicol in meningo-
coccal disease,7 it is imperative to advocate the possibili-
ties of use of pre-referral depot chloramphenicol at Pri-
mary Health Centres/or community during epidemics, 
which can be safely administered by trained health 
workers at community level.The strain of Neisseria 
meningitidis responsible for the epidemics in this study 
was Neisseria meningitidisserogroup A. 
 
This was similar to the strain that caused major epidem-
ics of CSM in northern Nigeria (1970, 1975, 1977, 1986 
and 1996), Chad (1988), and Niger Republic  (1991, 
1994).4Similarly, Neisseria meningitidis erogroup A 
was the cause of an epidemic reported by Moore et al,10 
in Saudi Arabia in 1987. The utility value of latex  
agglutination test in the diagnosis of meningitis was 
shown in this study.  
The latex test detected all the 77 cases and their sp cific 
serotypewhich would have been missed by CSF culture.  
The CSF culture detected only 5 (6.5%) cases. The low 
bacteriologic yield on CSF culture has implication n the 
sense that reasonable susceptibility testing to antibiotics 
can not be achieved which is a major set back for defin-
ing control measures.  The ability of the LPA test to 
detect specific serotype causing epidemic in a particular 
location and time has implication for effective contr l of 
the disease in terms of mass vaccine administration. The 
CSF culture isolates were all sensitive to ceftriaxone, 
chloramphenicol and ciprofloxacin. All the patients who 
survived, responded well to chloramphenicol; only a few 
5 (7.9%) of them have their antibiotic changed to  
ceftriaxone. The mortality rate of 10.4% in this study is 
higher than the 3.7% reported by Bwala et al5 in 
Maiduguri, in 1987.  
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